Maxigen Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	811.56	680.65	622.12	604.43	511.98
Revenue	811.56	680.65	622.12	604.43	511.98
Revenue Growth (YoY)	19.23%	9.41%	2.93%	18.06%	11.86%
Cost of Revenue	247.84	197.33	198.02	230.44	250.95
Gross Profit	563.72	483.33	424.09	373.99	261.03
Selling, General & Admin	183.89	176.98	205.45	141.03	92.38
Research & Development	126.11	111.97	68.6	99.63	75.68
Operating Expenses	302.68	303.42	274.24	245.38	171.08
Operating Income	261.04	179.91	149.85	128.62	89.95
Interest Expense	-0.04	-	-	-0.07	-0.2
Interest & Investment Income	35.28	27.43	25.02	3.18	0.48
Currency Exchange Gain (Loss)	3.83	17.14	4	31.69	-3.6
Other Non Operating Income (Expenses)	4.78	1.05	0.66	1.08	10.84
EBT Excluding Unusual Items	304.89	225.53	179.53	164.5	97.47
Gain (Loss) on Sale of Investments	-	0.02	-	-	-
Gain (Loss) on Sale of Assets	-	-0	13.62	1.03	-
Other Unusual Items	-	-	-	0.26	-
Pretax Income	304.89	225.55	193.14	165.78	97.47
Income Tax Expense	39.58	35.38	27.31	26.38	9.8
Net Income	265.31	190.17	165.83	139.4	87.67
Net Income to Common	265.31	190.17	165.83	139.4	87.67
Net Income Growth	39.52%	14.68%	18.95%	59.01%	38.47%
Shares Outstanding (Basic)	90	89	89	89	84
Shares Outstanding (Diluted)	90	90	89	89	85
Shares Change (YoY)	0.77%	0.27%	0.07%	5.78%	4.81%
EPS (Basic)	2.96	2.13	1.86	1.57	1.04
EPS (Diluted)	2.94	2.12	1.85	1.56	1.04
EPS Growth	38.68%	14.59%	18.59%	50.28%	31.75%
Free Cash Flow	208.36	266.45	148.76	254.05	103.34
Free Cash Flow Per Share	2.31	2.97	1.66	2.84	1.22
Dividend Per Share	-	0.830	1.000	0.476	-
Dividend Growth	-	-17.00%	110.00%	-	-
Gross Margin	69.46%	71.01%	68.17%	61.88%	50.98%
Operating Margin	32.16%	26.43%	24.09%	21.28%	17.57%
Profit Margin	32.69%	27.94%	26.66%	23.06%	17.12%
Free Cash Flow Margin	25.67%	39.15%	23.91%	42.03%	20.18%
EBITDA	293.07	206.75	177.09	156.71	119.73
EBITDA Margin	36.11%	30.38%	28.47%	25.93%	23.39%
D&A For EBITDA	32.03	26.85	27.24	28.09	29.79
EBIT	261.04	179.91	149.85	128.62	89.95
EBIT Margin	32.16%	26.43%	24.09%	21.28%	17.57%
Effective Tax Rate	12.98%	15.69%	14.14%	15.91%	10.05%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.